Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTHROMPLEX TOTAL versus standard 4F-PCC for urgent reversal of factor Xa inhibitor anticoagulation before surgery
2021-004138-12Phase 3Active
- Sponsor
- Takeda
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial comparing PROTHROMPLEX TOTAL with Standard of care 4F-PCC comparator (2 arms). Primary endpoint: Occurrence of intraoperative effective hemostasis. Started Feb 2022; status: active.
02
Drugs
Prothromplex Total
Beyond the preview
Go deeper on 2021-004138-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004138-12.